Investor Wildcat Capital Management, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Wildcat Capital Management, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-06-26 13D/A SLXN / Silexion Therapeutics Corp 1,020,852 113,428
2025-03-21 13G VICP / Vicapsys Life Sciences, Inc. 6,070,588
2024-12-12 13D/A US34407Y1111 / FLYING EAGLE ACQUISITION CORP_ WARRANTS EXP 2/26/27 0.00000000 0
2024-08-22 13D SLXN / Silexion Therapeutics Corp 1,020,852
2024-04-08 13G ULCC / Frontier Group Holdings, Inc. 28,061,351
2023-01-05 13D/A SKLZ / Skillz Inc. 21,265,819 19,596,988
2022-02-14 13G/A URGN / UroGen Pharma Ltd. 1,252,285 533,139
2021-03-23 13D/A SKLZ / Skillz Inc. 21,832,022 21,265,819
2021-03-08 13D/A SKLZ / Skillz Inc. 21,433,040 21,832,022
2021-02-12 13G/A URGN / UroGen Pharma Ltd. 1,155,862 1,252,285
2020-12-31 13D/A SKLZ / Skillz Inc. 21,433,050 21,433,040
2020-12-28 13D SKLZ / Skillz Inc. 21,433,050
2020-02-14 13G/A URGN / UroGen Pharma Ltd. 1,056,062 1,155,862
2019-10-04 13G URGN / UroGen Pharma Ltd. 1,056,062
2018-02-13 13G/A SRNE / Sorrento Therapeutics, Inc. 2,799,790 1,738,232
2018-02-13 13G/A IBRX / ImmunityBio, Inc. 808,974
2017-02-14 13G SRNE / Sorrento Therapeutics, Inc. 2,799,790 2,799,790
2016-06-22 13D/A SRNE / Sorrento Therapeutics, Inc. 2,799,790 2,799,790
2016-06-02 13D/A SRNE / Sorrento Therapeutics, Inc. 2,799,790 2,799,790
2016-05-16 13D/A SRNE / Sorrento Therapeutics, Inc. 2,799,790 2,799,790
2016-05-11 13D/A SRNE / Sorrento Therapeutics, Inc. 2,623,533 2,799,790
2016-05-06 13D/A SRNE / Sorrento Therapeutics, Inc. 2,623,533 2,623,533
2016-04-26 13D/A SRNE / Sorrento Therapeutics, Inc. 2,623,533 2,623,533
2016-04-18 13G SRNE / Sorrento Therapeutics, Inc. 2,623,533 2,623,533
2016-04-18 13D SRNE / Sorrento Therapeutics, Inc. 2,623,533